Business
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
– Presentations will highlight best- and/or first-in-class potential of four small molecule and biotherapeutic development candidates for investigation in
About this update from Exelixis, Inc.
[{"type":"text","content":"\n– Presentations will highlight best- and/or first-in-class potential of four small molecule and biotherapeutic development candidates for investigation in patients with advanced solid tumors –\n\n ALAMEDA, Calif.--(BUSINESS WIRE)--\nExelixis, Inc. (Nasdaq: EXEL) today announced that preclinical data will be presented for four pipeline molecules at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, IL.\n\n“We are excited to share preclinical data from four of our pipeline molecules that constitute the next phase in our commitment to the discovery and development of innovative cancer treatments,” said Dana T. Aftab, Ph.D., Executive Vice President, Discovery & Translational Research, and Chief Scientific Officer, Exelixis. “The results support the advancement into clinical development of these biotherapeutics and small molecules, as well as their potential to become best- and/or first-in-class therapies with differentiated clinical profiles.”\n\nExelixis will present preclinical data for XL495 and XL309, small molecules that have demonstrated synthetic lethality in the context of certain genetic anomalies frequently found in some tumors. Preclinical data will also be presented for the PD-L1xNKG2A-targeting bispecific antibody XB628 and the tissue factor-targeting antibody-drug conjugate XB371. Initial details about the poster presentations can be found below. Full data will be presented at the AACR Annual Meeting.\n\nAbstract 1733: XL495 is a potent, selective, and orally bioavailable inhibitor of PKMYT1\nLead Author: Dana Gwinn, Ph.D.\nSession Title: Kinase and Phosphatase Inhibitors 1\nMonday, April 28, 2:00-5:00 p.m. CT\nPreclinical results will be presented for XL495, a novel, potent small molecule inhibitor of PKMYT1. The inhibition of PKMYT1 is synthetically lethal in cells with genetic anomalies that lead to replication stress—a common occurrence in cancer cells but not in normal cells. Data from the analysis show XL495 has demonstrated the potential for anti-tumor activity alone and in combination with DNA-damaging agents. A phase 1 clinical study of XL495 in patients with locally advanced or metastatic solid tumors, both as monotherapy and in combination with select cytotoxic agents in tumor-specific indications, is underway.\n\nAbstract 2936: Preclinical charact...